- Trials with a EudraCT protocol (34)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
34 result(s) found for: parkinson.
Displaying page 1 of 2.
EudraCT Number: 2014-001014-25 | Sponsor Protocol Number: FBB-DBS-2014 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:Fundació Clínic per la Recerca Biomèdica | |||||||||||||
Full Title: Brain Amyloid-Beta burden as per florbetaben (Neuraceq) pet and cognitive outcomes after deep brain stimulation in Parkinsin's disease | |||||||||||||
Medical condition: Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004400-12 | Sponsor Protocol Number: FIRHSCSP/07/14 | Start Date*: 2007-12-27 | |||||||||||
Sponsor Name:Institut de Recerca de l'Hospital de la santa Creu i Sant Pau | |||||||||||||
Full Title: ENSAYO RANDOMIZADO A DOBLE CIEGO Y CONTROLADO CON PLACEBO DE RASAGILINA EN PACIENTES CON ENFERMEDAD DE PARKINSON Y SINTOMAS DE APATIA | |||||||||||||
Medical condition: Apatía en la Enfermedad de Parkinson | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-002408-32 | Sponsor Protocol Number: hspbi051916 | Start Date*: 2007-02-27 | |||||||||||
Sponsor Name:Institut de Recerca del Hospital de la Santa Creu i Sant Pau | |||||||||||||
Full Title: Modulación dopaminérgica de las funciones cognitivas y afectivas por el tratamiento con diferentes métodos de estimulación dopaminérgica en la enfermedad de Parkinson . Implicaciones para el tratam... | |||||||||||||
Medical condition: Fluctuaciones motoras, cognitivas y del humor en la enfermedad de Parkinson. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004229-10 | Sponsor Protocol Number: DESCIFRA03 | Start Date*: 2014-07-07 |
Sponsor Name:Raul de la Fuente-Fernandez | ||
Full Title: Placebo responses in different stages of frontostriatal dysfunction in Parkinson's disease | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2022-001751-17 | Sponsor Protocol Number: IIBSP-DON-2022-43 | Start Date*: 2023-07-27 |
Sponsor Name:Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau | ||
Full Title: Multicenter, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of donepezil versus placebo in mild cognitive impairment associated with Parkinson's disease | ||
Medical condition: Parkinson's disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-001132-10 | Sponsor Protocol Number: OS320-3006 | Start Date*: 2014-10-23 | |||||||||||
Sponsor Name:Osmotica Pharmaceutical Corp. | |||||||||||||
Full Title: A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects with Levodo... | |||||||||||||
Medical condition: Parkinson's Disease Subjects with Levodopa-Induced Dyskinesias | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-000364-21 | Sponsor Protocol Number: PI1102031 | Start Date*: 2012-11-13 | |||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomédica | |||||||||||||
Full Title: FDDNP-PET FOR IN VIVO DIAGNOSIS OF TAUOPATHY IN UNCLASSIFIABLE PARKINSONISM | |||||||||||||
Medical condition: Atypical Parkinsonism | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-001063-27 | Sponsor Protocol Number: JZP385-202-01 | Start Date*: 2023-07-19 | |||||||||||
Sponsor Name:Cavion, Inc., a subsidiary of Jazz Pharmaceuticals, Inc. | |||||||||||||
Full Title: A 17-week, Phase 2, Randomized, Double-blind, Placebo-controlled, Flexible-dosing, Parallel-group, Multicenter Study of the Efficacy and Safety of Suvecaltamide in the Treatment of Moderate to Seve... | |||||||||||||
Medical condition: Parkinson’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004335-36 | Sponsor Protocol Number: ANAVEX2-73-PDD-001 | Start Date*: 2018-07-04 |
Sponsor Name:Anavex Life Sciences Corp. | ||
Full Title: A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Parkinson’s Disease with Dementia Patients. | ||
Medical condition: Cognition in Parkinson’s Disease with dementia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002678-29 | Sponsor Protocol Number: ANAVEX2-73-PDD-EP-001 | Start Date*: 2019-12-05 | ||||||||||||||||
Sponsor Name:Anavex Life Sciences Corp. | ||||||||||||||||||
Full Title: Open Label Extension Study for Patients with Parkinson’s Disease with Dementia Previously Enrolled in ANAVEX2-73-PDD-001 Study for Continued Safety Assessment | ||||||||||||||||||
Medical condition: Cognition in Parkinson’s Disease with Dementia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002627-16 | Sponsor Protocol Number: IRL752C003 | Start Date*: 2022-07-28 | |||||||||||
Sponsor Name:Integrative Research Laboratories Sweden AB (IRLAB) | |||||||||||||
Full Title: A randomised, placebo-controlled, multicentre phase IIb study evaluating the efficacy of pirepemat on falls frequency in patients with Parkinson’s disease | |||||||||||||
Medical condition: Parkinson’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) PL (Completed) FR (Completed) ES (Ongoing) NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004610-95 | Sponsor Protocol Number: 228PD201 | Start Date*: 2018-05-01 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, with an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 ... | |||||||||||||
Medical condition: Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) AT (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004849-20 | Sponsor Protocol Number: 283PD201 | Start Date*: 2023-03-22 | |||||||||||
Sponsor Name:Biogen Idec Research Limited | |||||||||||||
Full Title: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants with Parkinson’s Disease | |||||||||||||
Medical condition: Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) AT (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-000087-15 | Sponsor Protocol Number: BP39529 | Start Date*: 2017-12-21 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, 52-WEEK PHASE II STUDY TO EVALUATE THE EFFICACY OF INTRAVENOUS RO7046015/PRASINEZUMAB (PRX002) IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE WITH A 6... | |||||||||||||
Medical condition: Parkinson’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) AT (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002033-30 | Sponsor Protocol Number: ND0612L-007 | Start Date*: 2016-11-03 | |||||||||||
Sponsor Name:NeuroDerm Ltd. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo controlled, parallel group clinical study investigating the efficacy, tolerability, and safety of continuous subcutaneous ND0612 infusion Given as a... | |||||||||||||
Medical condition: Subjects with Parkinson’s Disease with motor fluctuations | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BE (Completed) FR (Completed) GB (Prematurely Ended) HU (Completed) NL (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003337-15 | Sponsor Protocol Number: CLR_18_06 | Start Date*: 2019-06-18 | |||||||||||
Sponsor Name:Sun Pharma Advanced Research Company (SPARC) Limited | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of K0706 in Subjects With Early Parkinson’s Disease | |||||||||||||
Medical condition: Early Parkinson’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) SK (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002818-16 | Sponsor Protocol Number: JM-010CS-OL | Start Date*: 2022-12-30 | |||||||||||
Sponsor Name:Contera Pharma A/S | |||||||||||||
Full Title: Open-Label Extension Study of JM-010 in Parkinson’s Disease Patients With Dyskinesia | |||||||||||||
Medical condition: Parkinson's Disease Patients with Dyskinesia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) ES (Ongoing) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005653-24 | Sponsor Protocol Number: IRB00003099 | Start Date*: 2021-06-28 |
Sponsor Name:Clínica Integral del pie-Ana Sans | ||
Full Title: Effectiveness of botulinum toxin infiltration in spasticity of the 1st toe in patients with neurological pathology | ||
Medical condition: The application of Botox is described in the technical sheet for spasticity and has already been applied to the foot. This is how we speak of a phase IV clinical trial, with a low level of interven... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002949-38 | Sponsor Protocol Number: CVL-751-PD-001 | Start Date*: 2020-02-06 |
Sponsor Name:Cerevel Therapeutics, LLC | ||
Full Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEAS... | ||
Medical condition: Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Prematurely Ended) CZ (Completed) DE (Completed) FR (Completed) PL (Completed) ES (Ongoing) BG (Completed) IT (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-002144-85 | Sponsor Protocol Number: M15-741 | Start Date*: 2019-07-29 | |||||||||||
Sponsor Name:AbbVie Deutschland | |||||||||||||
Full Title: A 52-Week, open-label, single-arm study to evaluate the safety and tolerability of 24-hour daily exposure of continuous subcutaneous infusion of ABBV-951 in subjects with Parkinson's disease | |||||||||||||
Medical condition: Parkinson's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DK (Completed) NL (Completed) ES (Completed) BE (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
